Literature DB >> 26195522

Age-Stratified Treatment Response Rates in Hospitalized Patients with Clostridium difficile Infection Treated with Metronidazole.

Vy P Pham1, Andrea M Luce2, Sara C Ruppelt3, Wenjing Wei4, Samuel L Aitken5, William L Musick6, Ryan K Roux5, Kevin W Garey7.   

Abstract

Consensus on the optimal treatment of Clostridium difficile infection (CDI) is rapidly changing. Treatment with metronidazole has been associated with increased clinical failure rates; however, the reasons for this are unclear. The purpose of this study was to assess age-related treatment response rates in hospitalized patients with CDI treated with metronidazole. This was a retrospective, multicenter cohort study of hospitalized patients with CDI. Patients were assessed for refractory CDI, defined as persistent diarrhea after 7 days of metronidazole therapy, and stratified by age and clinical characteristics. A total of 242 individuals, aged 60 ± 18 years (Charlson comorbidity index, 3.8 ± 2.4; Horn's index, 1.7 ± 1.0) were included. One hundred twenty-eight patients (53%) had severe CDI. Seventy patients (29%) had refractory CDI, a percentage that increased from 22% to 28% and to 37% for patients aged less than 50 years, for patients from 50 to 70 years, and for patients aged >70 years, respectively (P = 0.05). In multivariate analysis, Horn's index (odds ratio [OR], 2.04; 95% confidence interval [CI], 1.50 to 2.77; P < 0.001), severe CDI (OR, 2.25; 95% CI, 1.15 to 4.41; P = 0.018), and continued use of antibiotics (OR, 2.65; 95% CI, 1.30 to 5.39; P = 0.0072) were identified as significant predictors of refractory CDI. Age was not identified as an independent risk factor for refractory CDI. Therefore, hospitalized elderly patients with CDI treated with metronidazole had increased refractory CDI rates likely due to increased underlying severity of illness, severity of CDI, and concomitant antibiotic use. These results may help identify patients that may benefit from alternative C. difficile treatments other than metronidazole.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26195522      PMCID: PMC4576055          DOI: 10.1128/AAC.00816-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Increased rate of irritable bowel syndrome and functional gastrointestinal disorders after Clostridium difficile infection.

Authors:  S Sethi; K W Garey; V Arora; S Ghantoji; P Rowan; M Smolensky; H L DuPont
Journal:  J Hosp Infect       Date:  2010-12-28       Impact factor: 3.926

2.  A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection.

Authors:  Kevin W Garey; Shashank S Ghantoji; Dhara N Shah; Musarat Habib; Vaneet Arora; Zhi-Dong Jiang; Herbert L DuPont
Journal:  J Antimicrob Chemother       Date:  2011-09-21       Impact factor: 5.790

3.  High Horn's index score predicts poor outcomes in patients with Clostridium difficile infection.

Authors:  V Arora; S Kachroo; S S Ghantoji; H L Dupont; K W Garey
Journal:  J Hosp Infect       Date:  2011-06-22       Impact factor: 3.926

4.  Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy.

Authors:  C G M Jardin; H R Palmer; D N Shah; F Le; N D Beyda; Z Jiang; K W Garey
Journal:  J Hosp Infect       Date:  2013-07-05       Impact factor: 3.926

5.  Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.

Authors:  Stuart Johnson; Thomas J Louie; Dale N Gerding; Oliver A Cornely; Scott Chasan-Taber; David Fitts; Steven P Gelone; Colin Broom; David M Davidson
Journal:  Clin Infect Dis       Date:  2014-05-05       Impact factor: 9.079

6.  Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

Authors:  Stuart H Cohen; Dale N Gerding; Stuart Johnson; Ciaran P Kelly; Vivian G Loo; L Clifford McDonald; Jacques Pepin; Mark H Wilcox
Journal:  Infect Control Hosp Epidemiol       Date:  2010-05       Impact factor: 3.254

7.  Burden of Clostridium difficile infection in the United States.

Authors:  Fernanda C Lessa; Yi Mu; Wendy M Bamberg; Zintars G Beldavs; Ghinwa K Dumyati; John R Dunn; Monica M Farley; Stacy M Holzbauer; James I Meek; Erin C Phipps; Lucy E Wilson; Lisa G Winston; Jessica A Cohen; Brandi M Limbago; Scott K Fridkin; Dale N Gerding; L Clifford McDonald
Journal:  N Engl J Med       Date:  2015-02-26       Impact factor: 91.245

Review 8.  Treatment of Clostridium difficile infections.

Authors:  Melinda M Soriano; Stuart Johnson
Journal:  Infect Dis Clin North Am       Date:  2015-01-05       Impact factor: 5.982

9.  Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections.

Authors:  Kathleen M Mullane; Mark A Miller; Karl Weiss; Arnold Lentnek; Yoav Golan; Pamela S Sears; Youe-Kong Shue; Thomas J Louie; Sherwood L Gorbach
Journal:  Clin Infect Dis       Date:  2011-09       Impact factor: 9.079

10.  Unnecessary use of fluoroquinolone antibiotics in hospitalized patients.

Authors:  Nicole L Werner; Michelle T Hecker; Ajay K Sethi; Curtis J Donskey
Journal:  BMC Infect Dis       Date:  2011-07-05       Impact factor: 3.090

View more
  3 in total

Review 1.  [Clostridium difficile in the intensive care unit].

Authors:  F Prechter; A Stallmach
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-07-11       Impact factor: 0.840

Review 2.  Sleeping with the enemy: Clostridium difficile infection in the intensive care unit.

Authors:  Florian Prechter; Katrin Katzer; Michael Bauer; Andreas Stallmach
Journal:  Crit Care       Date:  2017-10-22       Impact factor: 9.097

3.  Increasing Age Has Limited Impact on Risk of Clostridium difficile Infection in an Elderly Population.

Authors:  Margaret A Olsen; Dustin Stwalley; Clarisse Demont; Erik R Dubberke
Journal:  Open Forum Infect Dis       Date:  2018-07-19       Impact factor: 3.835

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.